# Encoded Therapeutics Raises $275 Million to Advance Dravet Syndrome Drug and Expand Manufacturing

Encoded Therapeutics, a neuroscience-focused biotechnology company, has secured $275 million in a Series F financing round. The company will use the funds to advance its lead asset for Dravet syndrome and to scale up its internal manufacturing capabilities.

Dravet syndrome is a severe form of epilepsy that begins in infancy and is often resistant to existing treatments. Encoded’s therapy is designed to address the underlying genetic cause of the condition. The new capital will support clinical development of that program as well as investments in the company’s own production infrastructure.

The round was backed by Google’s venture arm, among other investors. Encoded has not disclosed a specific timeline for regulatory filings or trial readouts.

**Why this matters in biotech**

Gene-targeted therapies for rare neurological disorders remain a high-priority area in drug development. Dravet syndrome affects approximately one in 15,000 to 20,000 newborns, and few disease-modifying options exist. Encoded’s approach, combined with its push to build in-house manufacturing capacity, reflects a broader industry trend: companies are increasingly seeking to control production of complex genetic medicines rather than relying solely on contract manufacturers. This can shorten development timelines and reduce supply-chain risks. The size of the Series F round also signals sustained investor appetite for precision genetic therapies, even in a tighter capital market.

Source: [original report](https://www.fiercebiotech.com/biotech/encoded-executes-275m-raise-advance-dravet-syndrome-asset-and-scale-manufacturing)